The bank expects stronger tablet sales. It also points to lower margins and slower earnings growth for Novo Nordisk over the long run.
Recap by typeshit. Full story at MedWatch.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
New exploratory TOGETHER-PsO data from Lilly found broader immune and metabolic changes in people with psoriasis and obesity when Zepbound was added, showing up as early as week 12.
New TOGETHER-PsO data from Lilly: by week 36 the combo changed 482 proteins and 467 genes, against 140 and 16 with ixekizumab on its own.
Loading…